OMO 103
Alternative Names: OMO-103; OmomycLatest Information Update: 20 Jul 2024
At a glance
- Originator Peptomyc; Vall d-Hebron Research Institute
- Developer Peptomyc
- Class Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action Proto-oncogene protein c-myc inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Adenocarcinoma
- Preclinical Breast cancer; Colorectal cancer
- No development reported Lung cancer
Most Recent Events
- 31 May 2024 Pharmacokinetics and pharmacodynamics data from a phase I/II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 Aug 2023 Phase-I clinical trials in Adenocarcinoma (Combination therapy, Metastatic disease, Treatment-naive, Late-stage disease, First-line therapy) in Spain (IV) (NCT06059001)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Lung-cancer in Spain (IV)